Merck Canada Invests $33.2 million to Modernize Pointe Claire Manufacturing Facility in Quebec

OTTAWA, Nov. 1, 2011 /CNW/ - Rx&D President Russell Williams made the following statement to complement Merck Canada's announcement of the investment of $33.2 million to modernize its Pointe Claire Manufacturing facility.

"This investment has resulted in the expansion of the plant and installation of state-of-the-art production equipment, increasing the facility's efficiency and competitiveness internationally, while preserving local jobs. In total, $20 million of the overall investment went toward the purchase of goods and services from Quebec suppliers. The Pointe Claire plant employs 264 people and has been confirmed as a Centre of Excellence for manufacturing liquids, ointments and creams.

"The chance to make a significant contribution to the lives of Canadians and improve patient health and quality of life through research and innovation is what motivates Merck Canada and all those active in the life science community.

"It is by working together that we can consolidate the position of Canada as a potential world leader in the provision of health care solutions to people across the country and throughout the world. Creating a favorable environment by improving Canada's intellectual property and access regimes would greatly facilitate the attraction of additional life sciences investments in Canada by the innovative pharmaceutical sector that would benefit Canadian patients and the economy."

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents 15,000 men and women working for 50 member companies and invests more than $1 billion in research and development each year to fuel Canada's knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.

About Merck

Today's Merck is working to help the world be well. Merck is a global health care leader with a diversified portfolio of prescription medicines, vaccines, consumer and animal health products. In Canada, Merck markets over 530 pharmaceutical, consumer and animal health products and is a leader in a broad range of areas such as cardiology, immunology, infectious diseases, respiratory, vaccines, women's health and sun care. It is also focused on expanding offerings in other areas, including virology, oncology and diabetes.

Merck is one of the top R&D investors in Canada, with an investment of $78.6 million in 2010. Merck also has a large manufacturing facility in Québec dedicated to the annual production of some 35 million units including the Claritin® and Aerius® brands. Based in Montreal, Quebec, Merck employs over 1,400 people across Canada. For more information about our operations in Canada, visit www.merck.ca.

SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX

For further information:

Christine Choury
Media Relations
Telephone: 613.236.0455
E-mail: cchoury@canadapharma.org

Profil de l'entreprise

CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX&D)

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.